Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTPS1 | P17812 | 17/20 | 0.61 |
| ▸ | CTPS2 | Q9NRF8 | 3/20 | 0.61 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30528934 | 1.00 | CTPS1 (0.61) | CTPS1CTPS2GPR55DYRK1AKDR | |
| SCHEMBL30528901 | 0.92 | CTPS1 (0.59) | CTPS1CTPS2GPR55DYRK1A | |
| SCHEMBL22491620 | 0.92 | CTPS1 (0.59) | CTPS1CTPS2GPR55DYRK1A | |
| SCHEMBL22491696 | 0.89 | CTPS1 (0.77) | CTPS1CTPS2 | |
| SCHEMBL30528746 | 0.89 | CTPS1 (0.77) | CTPS1CTPS2 | |
| SCHEMBL22491676 | 0.86 | CTPS1 (0.80) | CTPS1CTPS2 | |
| SCHEMBL30528949 | 0.86 | CTPS1 (0.80) | CTPS1CTPS2 | |
| SCHEMBL22491716 | 0.85 | CTPS1 (0.81) | CTPS1CTPS2 | |
| SCHEMBL30528802 | 0.85 | CTPS1 (0.81) | CTPS1CTPS2 | |
| SCHEMBL21044219 | 0.79 | CTPS1 (0.72) | CTPS1CTPS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11655246-B2 | Aminothiazole compounds as inhibitors of CTPS1 | STEP PHARMA S.A.S. (FR) | 2023-05-23 | — | — | US | disclosed |
| US-11655246-B2 | Aminothiazole compounds as inhibitors of CTPS1 | STEP PHARMA S.A.S. (FR) | 2023-05-23 | — | — | US | disclosed |
| US-20210002269-A1 | COMPOUNDS | STEP PHARMA S.A.S. (FR) | 2021-01-07 | — | — | US | disclosed |
| WO-2020245665-A1 | N-(4-(5-CHLOROPYRIDIN-3-YL)PHENYL)-2-(2-(CYCLOPROPANESULFONAMIDO)PYRIMIDIN-4-YL) BUTANAMIDE DERIVATIVES AND RELATED COMPOUNDS AS HUMAN CTPS1 INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES | STEP PHARMA S.A.S. (FR) | 2020-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11655246-B2 | Aminothiazole compounds as inhibitors of CTPS1 | CTPS1, CTPS2, TBXAS1 | CTPS1 1/4885CTPS2 2/4885GPR55 4454/4885 |
| US-20210002269-A1 | COMPOUNDS | UGT1A1, CYP1A1, CYP19A1 | CTPS1 2385/4885CTPS2 2441/4885GPR55 4609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.